Role of surgical revascularization in diabetic patients with coronary artery disease

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 2, 2005, Pages 249-260

  Góngora, Enrique ^a   Sundt III, Thoralf M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angioplasty; Coronary artery bypass; Coronary artery disease; Stents; Survival; Total arterial coronary revascularization

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CARDIOVASCULAR AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; INSULIN; ORAL ANTIDIABETIC AGENT;

ARTERY GRAFT; CLINICAL TRIAL; CONSENSUS; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DIABETES MELLITUS; GENE THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; META ANALYSIS; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES;

CORONARY ARTERIOSCLEROSIS; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL REVASCULARIZATION;

EID: 15844391253     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.2.249     Document Type: Review

References (100)

1. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabet. Care20(9), 1396-1402 (1997).
2. Bjork S. The cost of diabetes and diabetes care. Diabet. Res. Clin. Pract. 54(Suppl. 1) S13-S18 (2001).
3. Boyle JP, Honeycutt AA, Narayan KMV et al. Projection of Diabetes Burden Through 2050: impact of changing demography and disease prevalence in the US. Diabet. Care 24(11), 1936-1940 (2001).
4. Mokdad AH, Ford ESM, Bowman BA et al. Diabetes trends in the USA: 1990-1998. Diabet. Care 23(9), 1278-1283 (2000).
5. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics. National Institutes of Health Publication 04-3892, Bethesda, MD, USA (2004).
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk-Factor Intervention Trial. Diabet. Care 16(2), 434-444 (1993).
7. Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am. J. Cardiol. 59(8), 750-755 (1987).
8. Borch-Johnsen K, Kreiner S, Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br. Med. J. Clin. Res. 294(6588), 1651-1654 (1987).
9. Krolewski AS, Warram JH, Rand LI, Kah CR. Epidemiologic approach to the etiology of Type I diabetes mellitus and its complications. N. Engl. J. Med. 317(22), 1390-1398 (1987).
10. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am. Heart J. 110(5), 1100-1107 (1985).
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229-234 (1998).
12. Stone PH, Muller JE, Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left-ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left-ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J. Am. Col. Cardiol. 14(1), 49-57 (1989).
13. Savage MP, Krolewski AS, Kenien GG et al. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am. J. Cardiol. 62(10 Pt 1), 665-669 (1998)
14. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabet. Care 21(1), 69-75 (1998).
15. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J. Am. Col. Cardiol. 44(5), 1146-1154 (2004).
16. Anonymous. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 68(5), 939-950 (1983).
17. Anonymous. 11-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. N. Engl. J. Med. 311(21), 1333-1339 (1984).
18. Anonymous. Long-term results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet 2(8309), 1173-1180 (1982).
19. Norris RM, Agnew TM, Brandt PW et al. Coronary surgery after recurrent myocardial infarction: progress of a trial comparing surgical with nonsurgical management for asymptomatic patients with advanced coronary disease. Circulation 63(4), 785-792 (1981).
20. Mathur VS, Guinn GA. Prospective randomized study of the surgical therapy of stable angina. Cardiovasc. Clin. 8(2), 131-144 (1977).
21. Kloster FE, Kremkau EL, Ritzmann LW et al. Coronary bypass for stable angina: a prospective randomized study. N. Engl. J. Med. 300(4), 149-157 (1979).
22. Yusuf S, Zucker D, Peduzzi P et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344(8922), 563-570 (1994) Erratum: Lancet 344(8934), 1446 (1994).
23. Alderman EL, Bourassa MG, Cohen LS et al. 10-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study (CASS). Circulation 82(5), 1629-1646 (1990).
24. Takaro T, Hultgen HN, Lipton MJ, Detre KM. The VA cooperative randomized study of surgery for coronary arterial occlusive disease II. Subgroup with significant left main lesions. Circulation 54(Suppl. 6) (1976).
25. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction. N. Engl. J. Med. 312(26), 1665-1671 (1985).
26. Peduzzi P, Hultgren HN. Effect of medical vs. surgical treatment on symptoms in stable angina pectoris. The Veterans Administration Cooperative Study of surgery for coronary arterial occlusive disease. Circulation 60(4), 888-900 (1979).
27. Mock B, Fisher LD, Holmes DR Jr. et al. Comparison of effects of medical and surgical therapy on survival in severe angina pectoris and two-vessel coronary artery disease with and without left-ventricular dysfunction: a Coronary Artery Surgery Study Registry Study. Am. J. Cardiol. 61(15), 1198-1203 (1998).
28. Weiner DA, Ryan TJ, McCabe CH et al. The role of exercise testing in identifying patients with improved survival after coronary artery bypass surgery. J. Am. Col. Cardiol. 8(4), 741-748 (1986).
29. Davies RF, Goldberg AD, Forman S et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 95(8), 2037-2043 (1997).
30. Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N. Engl. J. Med. 342 (14), 989-997 (2000).
31. Anonymous. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J. Am. Col. Cardiol. 35 (5), 1122-1129 (2000).
32. Detre KM, Holubkov R, Coronary revascularization on balance. Robert L. Frye lecture. Mayo. Clin Proc. 77(1), 72-82 (2002).
33. Van Belle E, Ketelers R, Bauters C et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 103 (9), 1218-1224 (2001).
34. Carson JL, Scholz PM, Chen AY et al. Diabetes mellitus increases short-term mortality and mordibity in patients undergoing coronary artery bypass graft surgery. J. Am. Col. Cardiol. 40(3), 418-423 (2002).
35. Furnary AP, Gao G, Grunkemeir GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. 125(5), 1007-1021 (2003).
36. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann. Thorac. Surg. 67(2), 352-360 (1999).
37. McAlister FA, Man J, Bistritz L, Amad H, Tandon P. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabet. Care 26(5), 1518-1524 (2003).
38. Zerr KJ, Furnary AP, Grunkemeier GL et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann. Thorac. Surg. 63(2), 356-361 (1997).
39. Anonymous. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N. Engl. J. Med. 335(4), 217-225 (1996).
40. Calafiore AM, Di Mauro M, Di Giammarco G et al. Effect of diabetes on early and late survival after isolated first coronary bypass surgery in multivessel disease. J. Thorac. Cardiovasc. Surg. 125(1), 144-154 (2003).
41. Leavitt BJ SL, Maloney C, Clough RA et al. Northern New England Cardiovascular Disease Study Group. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation 110 (11 Suppl. 1), II41-II44 (2004).
42. Alderman EL, Kip KE, Whitlow PL et al. Native coronary disease progression exceeds failed revascularization as cause of angina after 5 years in the Bypass Angioplasty Revascularization Investigation (BARI). J. Am. Col. Cardiol. 44(4), 766-774(2004).
43. Campeau L, Enjalbert M, Lesperance J et al. The relation of risk factors to the development of atherosclerosis in saphenousvein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N. Engl. J. Med. 311(21),1329-1332 (1984).
44. Campeau L, Enjalbert M, Lesperance J et al. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. Circulation 68(3 Pt 2(1983).
45. Chesebro JH, Fuster V, Elveback LR et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N. Engl. J. Med. 310(4), 209-214 (1984).
46. Lorenz RL, Schacky CV, Weber M et al. Improved aortocoronaty bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet 1(8389), 1261-1264 (1984).
47. Goldman S, Copeland J, Moritz T et al. Internal mammary artery and saphenous vein-graft patency. Effects of aspirin. Circulation 82(Suppl. 5) (1990).
48. Mangano DT, Multicenter Study of Perioperative Ischemia Research G. Aspirin and mortality from coronary bypass surgery. N. Engl. J. Med. 347(17), 1309-1317 (2002).
49. Anonymous. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes on saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N. Engl. J. Med. 336(3), 153-162 (1997).
50. Brophy JM, Bourgault C, Brassard P. The use of cholesterol-lowering medications after coronary revascularization. Canadian Med. Assoc. J. 169(11), 1153-1157 (1153).
51. Foody JM, Ferdinand FD, Galusha D et al. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 108(1), 9 (2003).
52. Mann MJ, Whittemore AD, Donaldson MC et al. Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet 354(9189), 1493-1498 (2003).
53. Mann MJ. Transcription factor decoys for the prevention of vein bypass graft failure. Am. J. Cardiovasc. Drug 3(2), 79-85 (2003).
54. Zulli A, Hare DL, Horrigan M, Buxton BF. The resistance of the IMA to atherosclerosis might be associated with its higher eNOS, ACE and ET-A receptor immunoreactivity. Arterioscler. Thromb. Vasc. Biol. 23(7), 1 (2003).
55. Gaudino M, Toesca A, Maggiano N, Pragliola C, Possati G. Localization of nitric oxide synthase Type III in the internal thoracic and radial arteries and the great saphenous vein: a comparative immunohistochemical study. J. Thorac. Cardiovasc. Surg. 125(6), 1510-1515 (2003).
56. Barner HB, Standeven JW, Reese J. Twelve-year experience with internal mammary artery for coronary artery bypass J. Thorac. Cardiovasc. Surg. 90(5), 668-675 (1985).
57. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann. Thorac. Surg. 77(1), 93-101 (2004).
58. Loop FD, Lytle BW, Cosgrove DM et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N. Engl. J. Med. 314(1), 1-6 (1986).
59. Schwartz L, Kip KE, Frye RL et al. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 106(21), 2652-2658 (2002).
60. Whitlow PL, Dimas AP, Bashore TM et al. Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI). J. Am. Col. Cardiol. 34(6), 1750-1759 (1999).
61. Anonymous. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96(6), 1761-1769 (1997).
62. Buxton BF, Komeda M, Fuller JA, Gordon I. Bilateral internal thoracic artery grafting may improve outcome of coronary artery surgery. Risk-adjusted survival. Circulation 98(Suppl. 19), 10 (1998).
63. Lytle BW, Blackstone EH, Loop FD et al. Two internal thoracic artery grafts are better than one. J. Thorac. Cardiovasc. Surg. 117(5), 855-872 (1999).
64. Matsa M, Paz Y, Gurevitch J et al. Bilateral skeletonized internal thoracic artery grafts in patients with diabetes mellitus. J. Thorac. Cardiovasc. Surg. 121(4), 668-674 (2001).
65. Calafiore AM, Vitolla G, Iaco AL et al. Bilateral internal mammary artery grafting: midterm results of pedicled versus skeletonized conduits. Ann. Thorac. Surg. 67(6), 1637-1642 (1999).
66. Dion R, Glineur D, Derouck D et al. Long-term clinical and angiographic follow-up of sequential internal thoracic artery grafting. Euro. J. Cardio. Thorac. Surg. 17(4), 407-414 (2000).
67. Tector AJ, Kress DC, Downey FX, Schmahl TM. Complete revascularization with internal thoracic artery grafts. Semin Thorac. Cardiovasc. Surg. 8(1), 29-41 (1996).
68. Tector AJ, McDonald ML, Kress DC, Downey FX, Schmahl TM. Purely internal thoracic artery grafts: outcomes. Ann. Thorac. Surg. 72(2), 450-455 (2001).
69. Sauvage LR, Rosenfeld JG, Roby PV et al. Internal thoracic artery grafts for the entire heart at a mean of 12 years. Ann. Thorac. Surg. 75(2), 501-504 (2003).
70. Barner HB, Sundt TM 3rd, Bailey M, Zang Y. Midterm results of complete arterial revascularization in more than 1,000 patients using an internal thoracic artery/radial artery T graft. Ann. Surg. 234(4), 447-452 (2001).
71. Lev-Ran O, Mohr R, Pevni D et al. Bilateral internal thoracic artery grafting in diabetic patients; short-term and long-term results of a 515-patients series. J. Thorac. Cardiovasc. Surg 127(4), 1145-1150 (2004).
72. Lev-Ran O, Braunstein R, Nesher N et al. Bilateral versus single internal thoracic artery grafting in oral-treated diabetic subsets: comparative seven-year outcome analysis. Ann. Thorac. Surg. 77(6), 2039-2045 (2004).
73. Lev-Ran O, Mohr R, Amir K et al. Bilateral internal thoracic artery grafting in insulin-treated diabetics: should it be avoided? Ann. Thorac. Surg. 75(6). 1872-1877 (2003).
74. Muneretto C, Negri A, Manfredi J et al. Safety and usefulness of composite grafts for total arterial myocardial revascularization: a prospective randomized evaluation. J. Thorac. Cardiovasc. Surg. 125(4), 826-835 (2003).
75. Muneretto C, Bisleri G, Negri A et al. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. Circulation 108(1), 9 (2003).
76. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301(2), 61-68 (1979).
77. Kip KE, Faxon DP, Detre KM et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94(8), 1818-1825 (1996).
78. Stein B, Weintrub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 91(4), 979-989 (1995).
79. Van Belle E, Chmair A, Bauters C, Lablanche JM. Angioplasty in the diabetic patient. J Invas. Cardiol. 16(1), 23-27 (2004)
80. Rozenman Y, Sapoznikov D, Mosseti M et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation. J. Am. Col. Cardiol. 30(6), 1420-1425 (1997).
81. Bhatt DL, Marso SP, Lincoff AM et al. Abciximab reduces mortality in diabetics following precutaneous coronary intervention. J. Am. Col. Cardiol. 35(4), 922-928 (2000).
82. Van Belle E, Bauters C, Hubert E et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 96(5), 1454-1460 (1997).
83. Van Belle E, Perie M, Braune D et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J. Am. Col. Cardiol. 40(3), 410-417 (2002).
84. Kelsey SF. Patients with diabetes did better with coronary bypasss graft surgery than with percutaneous transluminal coronary angioplasty: was this BARI finding real? Am. Heart J. 138 (5 Pt 1), S387-S393 (1999).
85. King SB 3rd, Lembo NJ, Weintraub WS et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N. Engl. J. Med. 331(16), 1044-1050 (1994).
86. King SB 3rd, Kosinski AS, Guyton RA, Lembo NJ, Weintrub WS. 8-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) J. Am. Col. Cardiol. 35(5), 1116-1121 (2000).
87. Kurbaan AS, Bowker TJ, Ilsley CD et al. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode Am. J. Cardiol. 87(8), 947-950 (2001).
88. Henderson RA, Pocock SJ, Sharp SJ et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 352(9138), 1419-1425 (1998).
89. Niles NW, McGrath PD, Malenka D et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J. Am. Col. Cardiol. 37(4), 1008-1015 (2001).
90. Barsness GW, Peterson ED, Ohman EM et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty Circulation 96(8), 2551-2556 (1997).
91. Abizaid A, Costa MA, Centemero M et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial Circulation 104(5), 533-538 (2001).
92. Legrand VM, Serruys PW, Unger F et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 109(9), 1114-1120 (2004).
93. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomized controlled trial. Lancet 360(9338), 965-970 (2002).
94. Rodriguez A, Rodriguez Alemparte M, Baldi J et al. Coronary stenting versus coronary bypass surgery in patients with nultiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. Heart 89(2), 184-188 (2003).
95. Locker C, Mohr R, Lev-Ran O et al. Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients. Ann. Thorac. Surg. 78, 471-475 (2004).
96. Hlatky MA, Boothroyd D, Melsop KA et al. Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Artery Disease. Circulation 110, 1960-1966 (2004).
97. Zhang Z, Mahoney EM, Stables RH et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one year results from the Stent or Surgery trial. Circulation 108 (14), 1694-1700 (1964).
98. Hlatky MA, Rogers WJ, Johnstone I et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N. Engl. J. Med. 336(2), 92-99 (1997).
99. Sobel BE, Frye R, Detre KM, Bypass Angioplasty Revascularization Investigation 2 Diabetes T. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 107(4), 636-642 (2003).
100. Smith D. The CARDia trial protocol. Heart 89(10), 1125-1126 (2003).